Scilex Holding Company Financing Cash Flow
Scilex Holding Company (SCLX) reported Financing Cash Flow of $4.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Scilex Holding Company net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$4.48M.
- Scilex Holding Company net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $9.14M.
- Scilex Holding Company net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $17.52M.
- Scilex Holding Company net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$11.30M.
- Scilex Holding Company net cash provided by (used in) financing activities for fiscal 2025 was -$5.46M.
- Scilex Holding Company net cash provided by (used in) financing activities for fiscal 2024 was -$18.13M, a 176.88% decline from fiscal 2023.
- Scilex Holding Company net cash provided by (used in) financing activities for fiscal 2023 was $23.58M, a 11.39% increase from fiscal 2022.
- Scilex Holding Company net cash provided by (used in) financing activities for fiscal 2022 was $21.17M, a 24.83% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 7 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 10 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.66M 10-Q · filed 2026-08-14 | $22.18M derived: sum of 3 quarters · filed 2026-08-14 | $10.88M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2026-03-31 | $9.14M 10-Q · filed 2026-05-20 | $26.66M derived: sum of 2 quarters · filed 2026-05-20 | $15.37M derived: sum of 3 quarters · filed 2026-05-20 | $6.77M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-12-31 | $17.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $6.22M derived: sum of 2 quarters · filed 2026-04-10 | -$2.38M derived: sum of 3 quarters · filed 2026-08-14 | -$5.46M 10-K · filed 2026-04-10 | ||||||
| 2025-09-30 | -$11.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$19.90M derived: sum of 2 quarters · filed 2026-08-14 | -$22.98M 10-Q · filed 2025-11-14 | -$30.16M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-06-30 | -$8.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$11.68M 10-Q · filed 2026-08-14 | -$18.86M derived: sum of 3 quarters · filed 2026-08-14 | -$23.35M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-03-31 | -$3.08M 10-Q · filed 2026-05-20 | -$10.27M derived: sum of 2 quarters · filed 2026-05-20 | -$14.75M derived: sum of 3 quarters · filed 2026-05-20 | -$10.02M derived: sum of 4 quarters · filed 2026-05-20 | ||||||
| 2024-12-31 | -$7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$11.67M derived: sum of 2 quarters · filed 2026-04-10 | -$6.93M derived: sum of 3 quarters · filed 2026-04-10 | -$18.13M 10-K · filed 2026-04-10 | ||||||
| 2024-09-30 | -$4.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $248.00K derived: sum of 2 quarters · filed 2025-11-14 | -$10.95M 10-Q · filed 2025-11-14 | -$2.64M derived: sum of 4 quarters · filed 2025-11-14 | ||||||
| 2024-06-30 | $4.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$6.46M 10-Q · filed 2025-08-13 | $1.84M derived: sum of 3 quarters · filed 2025-08-13 | -$37.05M derived: sum of 4 quarters · filed 2025-08-13 | ||||||
| 2024-03-31 | -$11.20M 10-Q · filed 2025-05-14 | -$2.89M derived: sum of 2 quarters · filed 2025-05-14 | -$41.78M derived: sum of 3 quarters · filed 2025-05-14 | $1.76M derived: sum of 4 quarters · filed 2025-05-14 | ||||||
| 2023-12-31 | $8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$30.59M derived: sum of 2 quarters · filed 2025-03-31 | $12.95M derived: sum of 3 quarters · filed 2025-03-31 | $23.58M 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | -$38.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $4.65M derived: sum of 2 quarters · filed 2025-01-17 | $15.28M 10-Q · filed 2025-01-17 | $15.70M derived: sum of 4 quarters · filed 2025-01-17 | ||||||
| 2023-06-30 | $43.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $54.17M 10-Q · filed 2024-08-13 | $54.59M derived: sum of 3 quarters · filed 2024-08-13 | $47.73M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $10.63M 10-Q · filed 2024-05-13 | $11.05M derived: sum of 2 quarters · filed 2024-05-13 | $4.19M derived: sum of 3 quarters · filed 2024-05-13 | -$8.16M derived: sum of 4 quarters · filed 2024-05-13 | ||||||
| 2022-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$6.44M derived: sum of 2 quarters · filed 2024-03-12 | -$18.79M derived: sum of 3 quarters · filed 2024-03-12 | $21.17M 10-K · filed 2024-03-12 | ||||||
| 2022-09-30 | -$6.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$19.21M derived: sum of 2 quarters · filed 2023-11-14 | $20.75M 10-Q · filed 2023-11-14 | -$37.32M 10-Q · filed 2022-11-04 | -$91.25M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-06-30 | -$12.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $27.61M 10-Q · filed 2023-08-11 | $3.54M 10-Q · filed 2022-08-12 | -$84.38M derived: sum of 3 quarters · filed 2024-03-12 | -$84.38M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2022-03-31 | $39.96M 10-Q · filed 2023-05-12 | $1.53M 10-Q · filed 2022-05-16 | -$72.04M derived: sum of 2 quarters · filed 2024-03-12 | -$72.04M derived: sum of 3 quarters · filed 2024-03-12 | $68.12M derived: sum of 4 quarters · filed 2024-03-12 | |||||
| 2021-12-31 | -$112.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$112.00M derived: sum of 2 quarters · filed 2024-03-12 | $28.16M derived: sum of 3 quarters · filed 2024-03-12 | $28.16M 10-K · filed 2024-03-12 | $140.66M 10-K · filed 2022-02-24 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $140.16M derived: sum of 2 quarters · filed 2022-11-04 | $140.16M 10-Q · filed 2022-11-04 | |||||||
| 2021-06-30 | $140.16M 10-Q/A · filed 2021-08-24 | $140.16M 10-Q · filed 2022-08-12 | ||||||||
| 2021-03-31 | $140.16M 10-Q · filed 2022-05-16 | |||||||||
| 2020-12-31 | $31.79K 10-K · filed 2022-02-24 | -$19.17M 10-K · filed 2023-03-07 | ||||||||
| 2020-09-30 | $79.72K 10-Q/A · filed 2021-12-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |